Answers are grounded in this paper and cite their sources.
Demonstrates a new device detecting multiple blood biomarkers in metabolic diseases, suggesting improved point-of-care testing.
produced from metabolites by their corresponding oxidases can oxidize TMB to generate a colored product, ox-TMB, for quantification with a smartphone. We demonstrated the MOG-μPAD to be sensitive, biomarker-specific, cost-effective, easy-to-use, and stable for storage. We further developed the MOG-μPAD with multiple sensing regions for simultaneously detecting multiple blood biomarkers such as glucose, uric acid, xanthine, and creatinine to monitor numerous metabolic disorders in one run. This offers a new multiplex POCT strategy for detecting the pathogenesis, progression, and prognosis of multiple diseases concurrently, which can be expanded to quantify other biomarkers.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: